Melinta Therapeutics (MLNT) Getting Somewhat Negative Press Coverage, Report Shows
Headlines about Melinta Therapeutics (NASDAQ:MLNT) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Melinta Therapeutics earned a news impact score of -0.01 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.9942570700122 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s rankings:
- Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference – GlobeNewswire (press release) (globenewswire.com)
- Melinta Therapeutics, Inc. (MLNT) Expected to Post Quarterly Sales of $3.28 Million (americanbankingnews.com)
- Melinta Therapeutics (MLNT) Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE in Patients with cUTI (streetinsider.com)
- Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018 (finance.yahoo.com)
Several research firms have issued reports on MLNT. Zacks Investment Research downgraded Melinta Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. ValuEngine upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Gabelli upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. BidaskClub downgraded Melinta Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Ladenburg Thalmann Financial Services upgraded Melinta Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, November 30th. Three analysts have rated the stock with a sell rating, five have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $3.56.
In other Melinta Therapeutics news, Director Vatera Healthcare Partners Llc acquired 5,777,778 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were bought at an average price of $13.50 per share, for a total transaction of $78,000,003.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.50% of the company’s stock.
About Melinta Therapeutics
Melinta Therapeutics, Inc develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.